Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease
Clinical trial NCT05388149 · RECRUITING
Trial details
- NCT number
- NCT05388149
- Sponsor
- University Health Network, Toronto
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-06
- Primary completion
- 2026-07-01
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.